Compare Stocks: RADX, BDTX, GNLX, and INO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.23	$1.91	$1.60 ▼ $4.94	$128.11M	3.28	587,186 shs	521,910 shs
GNLX Genelux	$2.66	$2.84	$2.29 ▼ $8.53	$120.35M	0.6	390,509 shs	415,357 shs
INO Inovio Pharmaceuticals	$1.29	$1.05	$0.56 ▼ $2.98	$133.38M	1.52	4.90 million shs	1.70 million shs
RADX Radiopharm Theranostics	$2.41	$3.51	$2.04 ▼ $16.25	$34.85M	1.63	71,374 shs	333,279 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	0.00%	+0.90%	+31.95%	-1.33%	-18.91%
GNLX Genelux	0.00%	-2.21%	-9.52%	-10.44%	-20.12%
INO Inovio Pharmaceuticals	0.00%	+9.32%	+90.55%	+0.78%	-45.57%
RADX Radiopharm Theranostics	0.00%	-1.23%	-23.49%	-48.50%	-56.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDTX Black Diamond Therapeutics	$2.23	$1.91	$1.60 ▼ $4.94	$128.11M	3.28	587,186 shs	521,910 shs
GNLX Genelux	$2.66	$2.84	$2.29 ▼ $8.53	$120.35M	0.6	390,509 shs	415,357 shs
INO Inovio Pharmaceuticals	$1.29	$1.05	$0.56 ▼ $2.98	$133.38M	1.52	4.90 million shs	1.70 million shs
RADX Radiopharm Theranostics	$2.41	$3.51	$2.04 ▼ $16.25	$34.85M	1.63	71,374 shs	333,279 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDTX Black Diamond Therapeutics	0.00%	+0.90%	+31.95%	-1.33%	-18.91%
GNLX Genelux	0.00%	-2.21%	-9.52%	-10.44%	-20.12%
INO Inovio Pharmaceuticals	0.00%	+9.32%	+90.55%	+0.78%	-45.57%
RADX Radiopharm Theranostics	0.00%	-1.23%	-23.49%	-48.50%	-56.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDTX Black Diamond Therapeutics	2.64	Moderate Buy	$9.80	339.46% Upside
GNLX Genelux	2.50	Moderate Buy	$18.00	576.69% Upside
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	145.48% Upside
RADX Radiopharm Theranostics	2.33	Hold	$11.00	356.43% Upside

Current Analyst Ratings Breakdown

Latest RADX, BDTX, GNLX, and INO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	GNLX Genelux	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Speculative Buy
8/13/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/13/2026	INO Inovio Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Positive	$1.80 ➝ $3.00
8/12/2026	INO Inovio Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2026	BDTX Black Diamond Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/6/2026	BDTX Black Diamond Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/6/2026	BDTX Black Diamond Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	INO Inovio Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$4.00
7/29/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	GNLX Genelux	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDTX Black Diamond Therapeutics	$70M	1.83	$0.53 per share	4.23	$1.97 per share	1.13
GNLX Genelux	$8K	15,043.96	N/A	N/A	$0.30 per share	8.87
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	$0.36 per share	N/A
RADX Radiopharm Theranostics	$2.35M	14.83	N/A	N/A	$3.52 per share	0.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDTX Black Diamond Therapeutics	$22.37M	-$0.75	N/A	N/A	N/A	N/A	-32.10%	-25.21%	11/5/2026 (Estimated)
GNLX Genelux	-$32.15M	-$0.86	N/A	N/A	N/A	N/A	-205.85%	-138.79%	11/4/2026 (Estimated)
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)
RADX Radiopharm Theranostics	-$24.83M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest RADX, BDTX, GNLX, and INO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	GNLX Genelux	-$0.1967	-$0.21	-$0.0133	-$0.21	N/A	N/A
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
8/5/2026	Q2 2026	BDTX Black Diamond Therapeutics	-$0.1954	-$0.17	+$0.0254	-$0.17	$5.56 million	N/A
7/31/2026	Q4 2026	RADX Radiopharm Theranostics	N/A	-$0.81	N/A	-$0.8050	N/A	$0.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDTX Black Diamond Therapeutics	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RADX Radiopharm Theranostics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDTX Black Diamond Therapeutics	N/A	7.28	7.28
GNLX Genelux	N/A	2.39	2.39
INO Inovio Pharmaceuticals	N/A	1.00	1.00
RADX Radiopharm Theranostics	N/A	3.01	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDTX Black Diamond Therapeutics	95.47%
GNLX Genelux	37.33%
INO Inovio Pharmaceuticals	26.79%
RADX Radiopharm Theranostics	N/A

Insider Ownership

Company	Insider Ownership
BDTX Black Diamond Therapeutics	9.29%
GNLX Genelux	7.50%
INO Inovio Pharmaceuticals	1.70%
RADX Radiopharm Theranostics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDTX Black Diamond Therapeutics	90	57.45 million	52.12 million	Optionable
GNLX Genelux	10	45.25 million	41.85 million	Not Optionable
INO Inovio Pharmaceuticals	320	103.40 million	101.64 million	Optionable
RADX Radiopharm Theranostics	N/A	14.46 million	N/A	N/A

RADX, BDTX, GNLX, and INO Headlines

Recent News About These Companies

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

August 26, 2026 | globenewswire.com

Radiopharm Theranostics (NASDAQ:RADX) Stock Price Down 8.4% - Here's Why

August 21, 2026 | americanbankingnews.com

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

August 20, 2026 | globenewswire.com

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

August 17, 2026 | finance.yahoo.com

RADX: RAD101 Topline & FY:26 Cash Flows

August 3, 2026 | finance.yahoo.com

Radiopharm Dips on Securities Pact

July 25, 2026 | baystreet.ca

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

July 24, 2026 | globenewswire.com

Radiopharm Highlights Data Release

July 23, 2026 | baystreet.ca

Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

July 22, 2026 | globenewswire.com

Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

July 22, 2026 | globenewswire.com

Radiopharm Theranostics Ltd ADR RADX

July 16, 2026 | morningstar.comM

Radiopharm Theranostics Limited Sponsored ADR

May 14, 2026 | cnn.com

RADX: Fiscal 3Q:26 Cash Flow Report

May 13, 2026 | finance.yahoo.com

Radiopharm Theranostics Ltd. ADR

May 13, 2026 | barrons.com

Radiopharm Theranostics ADR (RADX): Inside the Clinical Programs

April 28, 2026 | insidermonkey.com

Radiopharm Theranostics Reports Business Update

April 23, 2026 | globenewswire.com

Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer ...

April 20, 2026 | finance.yahoo.com

Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases

April 16, 2026 | markets.businessinsider.com

Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target increased by 752.98% to 39.26

April 16, 2026 | msn.com

Radiopharm Theranostics Limited - Depositary Receipt (RADX) price target decreased by 11.04% to 4.60

April 9, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX, BDTX, GNLX, and INO Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

$2.23 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$2.19 -0.04 (-1.97%)

As of 05:20 AM Eastern

Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Genelux NASDAQ:GNLX

$2.66 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$2.71 +0.05 (+1.84%)

As of 05:32 AM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Inovio Pharmaceuticals NASDAQ:INO

$1.29 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$1.29 0.00 (0.00%)

As of 05:39 AM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Radiopharm Theranostics NASDAQ:RADX

$2.41 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$2.48 +0.07 (+2.90%)

As of 05:12 AM Eastern

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RADX, BDTX, GNLX, and INO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RADX, BDTX, GNLX, and INO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RADX, BDTX, GNLX, and INO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX, BDTX, GNLX, and INO Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

Genelux NASDAQ:GNLX

Inovio Pharmaceuticals NASDAQ:INO

Radiopharm Theranostics NASDAQ:RADX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RADX, BDTX, GNLX, and INO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RADX, BDTX, GNLX, and INO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RADX, BDTX, GNLX, and INO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RADX, BDTX, GNLX, and INO Company Descriptions

Black Diamond Therapeutics NASDAQ:BDTX

Genelux NASDAQ:GNLX

Inovio Pharmaceuticals NASDAQ:INO

Radiopharm Theranostics NASDAQ:RADX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools